Latent Labs launches web-based AI model to democratize protein design
Latent Labs model has 'achieved state-of-the-art on different metrics' when testing the proteins it developed in a physical lab, according to Latent Labs CEO and founder Simon Kohl, a scientist who previously co-led DeepMind's AlphaFold's protein design team. State-of-the-art, or SOTA, is a term often used in the AI field that represents the industry's best performance to date on a specific task.
'We have computational ways of assessing how good the designs are,' he told TechCrunch, adding that a high percentage of proteins the model creates will be viable when tested in the lab.
The company's foundational biology model, known as LatentX, enables academic institutions, biotech startups, and pharmaceutical companies to design novel proteins directly in their browser using natural language.
LatentX goes beyond what's found in nature, creating entirely new molecule designs like nanobodies and antibodies with precise atomic structures. This approach can help develop new therapeutics at much faster rare.
This ability to design entirely new proteins is what distinguishes LatentX from the AlphaFold, according to Kohl.
'Alpha fold is a model for protein structure prediction. So it allows you to visualize existing structures, but it doesn't, it doesn't let you generate new proteins,' he said.
In contrast to AI-driven drug discovery companies like Xaira, Recursion or DeepMind spinout Isomorphic Labs, which focus on developing proprietary medicines, Latent Labs' business model involves licensing its model for use by external organizations.
'Not every company is in a position to build their own AI models, to have their own AI infrastructure, and to have their own AI teams,' Kohl said.
While LatentX is available for free, Kohl said the company intends to eventually charge for advanced features and capabilities as they're introduced.
Other companies providing open-sourced AI foundational models for drug discovery include Chai Discovery and EvolutionaryScale.
Latent Labs is backed by Radical Ventures, Sofinnova Partners, Google's Chief Scientist Jeff Dean, Anthropic's CEO Dario Amodei and Eleven Labs CEO Mati Staniszewski.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
29 minutes ago
- Business Wire
Paige and Oncoclínicas Strengthen Leadership in AI-Driven Cancer Diagnostics Across Brazil
NEW YORK & SíO PAULO--(BUSINESS WIRE)--Paige, a leader in next-generation AI technology, announced the continued and expanded use of its innovative AI-assisted diagnostic applications by long-time customer, Oncoclínicas&Co (Oncoclínicas), the largest private group of cancer care in Latin America. With a commitment to enhancing diagnostic capabilities and improving patient safety, Oncoclínicas has utilized Paige's technology across prostate and breast cancer diagnosis, supporting its commitment to advancing pathology standards throughout Brazil. Oncoclínicas employs a rigorous approach where all digitized prostate and breast cancer biopsy whole-slide images are analyzed by pathologists using AI as an adjunct diagnostic tool. This process provides extra layers of patient safety, enhancing both sensitivity and efficiency for the pathologists using the technology. Since August 2021, Oncoclínicas has utilized AI to support the review of over 23,000 prostate and breast biopsies. These results demonstrate the scale and commitment of Oncoclínicas to AI integration in their diagnostic workflow, which has led to Oncoclínicas' achieving: Faster second reader sign-out for senior pathologists using FullFocus™ and AI support. 1 Enhanced detection rates, including the identification of approximately .5% of precursor non-obligatory breast lesions that were not initially detected by pathologists. 1 Improved diagnostic consistency and efficiency through the use of Paige Prostate and Paige Breast AI Suites. 1 Dr. Leonard Medeiros da Silva, pathologist at OC Medicina de Precisão, an integrated laboratory of Oncoclínicas&Co dedicated to pathological anatomy, genetic testing and Big Data, reports a positive experience with Paige Prostate. "It aligns with Oncoclínicas published data showing nearly 100% sensitivity and 93% specificity,' he notes. 'The specialist also commends the technology's effectiveness in both cancer detection and accurate Gleason score determination.' 'We are proud to support Oncoclínicas in their mission to offer cutting-edge cancer diagnostic solutions,' said Dr. Juan Retamero, Medical Vice President at Paige. 'Their success in implementing AI technology is a testament to their dedication to clinical excellence and their forward-thinking approach to pathology. Our long-term partnership underscores Paige's commitment to providing access to high-quality AI technology globally, helping pathologists provide better diagnoses for their patients.' 'Over the past few months, I've had the opportunity to witness how the integration of digital pathology, biomarkers, AI, and genomics is accelerating the advancement of precision medicine, and, more importantly, improving patients' quality of life and offering new hope in the fight against cancer,' said Rodrigo Alvarenga, Operations Executive at Oncoclínicas&Co. 'At both the 2025 USCAP in Boston and ASCO in Chicago, it became clear that precision medicine is no longer a distant goal, but a present-day reality that can expand access to advanced technologies and enable more cost-effective care. We've reached an exciting point of no return, the convergence of AI, pathology, and genomics is not only transforming cancer care but is also critical to the long-term sustainability of our healthcare systems.' In Brazil, FullFocus™ and all AI assisted diagnostic applications such as the Paige Prostate Suite and the Paige Breast Suite are for Research Use Only. Not for use in diagnostic procedures. 1 Figures are based on independent clinical research conducted by Oncoclínicas&Co. Finding an average of 12,000 breast biopsies and surgical specimens were analyzed in 2024. The Paige Breast Suite as a second reader detected 55 non-obligatory precursor breast lesions that were not initially detected by pathologists. Additionally, after utilizing FullFocus™ with the Paige Prostate Suite, the average time to read a slide and complete a report reduced to one minute and 10 seconds. About Oncoclínicas&Co Oncoclínicas&Co is the largest group dedicated to cancer treatment in Latin America, with a highly specialized and innovative model focused on the oncology journey. With a medical staff of over 2,900 oncology specialists, the company operates in 40 Brazilian cities, totaling more than 140 units. Focused on research, technology, and innovation, the group has conducted approximately 682,000 treatments in the past 12 months. Oncoclínicas follows international standards of excellence, integrating outpatient clinics with high-complexity cancer centers, enhancing treatment through precision medicine and genomics. As the exclusive partner of the Dana-Farber Cancer Institute in Brazil, affiliated with Harvard Medical School, it has acquired Boston Lighthouse Innovation (USA) and holds a stake in MedSir (Spain). It is also part of the IDIVERSA index of B3, reinforcing its commitment to diversity. With the goal of expanding its global mission to overcome cancer, Oncoclínicas has entered Saudi Arabia through a joint venture with the Al Faisaliah Group, bringing its oncology expertise to a new continent. Learn more at: About Paige Paige is pushing the boundaries of AI to solve cancer's most critical issues, revolutionizing cancer care with next-generation technology. By leveraging exclusive access to millions of digitized pathology slides, clinical reports, and genomic data, Paige gains a holistic understanding of cancer, encompassing diverse factors such as gender, race, ethnicity, and geographical regions. This comprehensive data enables Paige to create advanced AI solutions that redefine cancer detection, diagnosis, and treatment. With a unique, intricate understanding of tissue, Paige sets new standards in precision diagnostics, earning the distinction of being the first FDA-cleared AI application in pathology. Paige has also developed the first million-slide foundation model for cancer, continuing to lead the way in uncovering novel insights and transforming them into life-changing products. For more information, visit
Forbes
31 minutes ago
- Forbes
Your Business' AI Has A Digital Immune System—Here's How To Protect It
Anand Oswal, SVP & GM of Network Security, Palo Alto Networks. In the last couple of years, artificial intelligence (AI) has transformed from a lab concept into the central nervous system of modern business, powering everything from developer tools to customer support. Now, with the rise of autonomous AI agents that can learn, reason and act on our behalf, we are not just using a new tool; we are introducing a new, dynamic entity into our corporate bodies. This represents a profound architectural shift. The old three-tier application stack was like a simple organism. The move to cloud computing modernized this system, but the fundamental constructs were similar. But the AI stack—with its models, new uses of data for training and inferencing, plugins and autonomous agents—is a whole new level of biological complexity. It can learn, adapt and interact in ways that are often unpredictable, which creates an entirely new landscape for potential attacks. Just like any highly evolved organism, this new digital nervous system is born vulnerable. It doesn't yet have the mature, battle-hardened immune system needed to defend against a new generation of sophisticated threats. To truly protect it, we need an equally sophisticated, built-in defense mechanism. Business leaders I talk to every day are keenly aware of this challenge. They see the immense promise and competitive advantage that AI offers, but they're also grappling with the hidden risks that come with adopting it. A common concern is the lack of visibility into which AI apps are running, what data they're accessing and what permissions they have. To navigate this new world confidently, security can no longer be a simple shield; it must evolve to be a comprehensive, adaptive immune system. This means building a defense system that is deeply integrated, intelligent and flexible enough to tell the difference between helpful and harmful actions, neutralize threats in real time and continuously learn from every interaction to become stronger and more resilient over time. Just as our own biological immune systems have evolved over millennia to protect us from countless unseen threats, our approach to cybersecurity must also evolve dramatically for the age of AI. Here's what that essential digital immune system needs to do: 1. Know Your Genetic Makeup: Proactive Scanning and Posture A healthy immune system starts with understanding its own body. For an AI ecosystem, this means having a complete, dynamic inventory of all components and actively screening every component before it enters your ecosystem. Start by integrating automated model scanning directly into your development pipeline. Before any open-source model is downloaded (from a repository like Hugging Face), it must be scanned for embedded malware, unsafe code within files or signs of model poisoning. To maintain the equivalent of a "healthy lifestyle," you will need to enforce strong posture management, monitoring your entire AI ecosystem for risks like excessive permissions or sensitive data exposure. This ensures your AI doesn't develop chronic vulnerabilities. You will also want to ensure that automated alerts notify you if, for example, a customer service chatbot attempts to access a sensitive financial database or if a developer grants an AI model overly broad permissions that violate the principle of least privilege. 2. Build Resilience Through Exposure: AI Red Teaming An immune system strengthens itself through controlled exposure, and your AI is no different. Go beyond theoretical assessments and implement an automated AI red teaming program that acts as a training ground against real-world attacks. You can begin by using established frameworks, such as the OWASP Top 10 for large language models, to simulate common attacks like prompt injection and data leakage. Take it to the next level by expanding your tests to include more than just technical risks, but also business-specific threats. For example, could an agent be tricked into issuing unauthorized refunds? Could a compromised internal tool manipulate a report for an executive? You must create a direct feedback loop where the findings from these red team exercises are used to immediately fine-tune models, update security filters and provide targeted training for your developers. 3. The Real-Time Immune Response: Runtime And Agent Security When an active threat emerges, the immune response must be swift and immediate. A key step is to implement protections at runtime, capable of analyzing the prompt intent and responses to block sophisticated injection attacks that built-in protections would miss. For autonomous agents, the stakes are even higher since agents have memory and the authority to use other tools. A truly robust digital immune system must be able to distinguish a healthy agent from one that has been hijacked, neutralizing its ability to cause harm from within. To do this, enforce the principle of least privilege by scoping out the tools and APIs each agent can access. For example, an agent designed to schedule meetings should have no ability to read emails. An additional safeguard would be ensuring you can automatically disable an agent if it is compromised or begins behaving erratically, like performing an unusual number of actions or making unusual data updates. Also, be sure to log every action taken by an agent, from the prompt it received to the tools it used and the output it generated, to ensure you can conduct effective forensic analysis if an incident occurs. Forging A Path In The AI Era To gain a competitive edge in today's fast-moving market, businesses must embrace AI's transformative power. But they simply can't do this with a compromised digital immune system. Relying on fragmented security tools that act merely as simple, isolated shields is no longer sufficient. What's needed is a holistic and integrated security approach that protects every single AI model, every dataset and every autonomous agent across the entire AI lifecycle, from development to deployment and ongoing operation. By proactively building and maintaining this comprehensive digital immune system, organizations not only protect their enterprise from evolving threats but also empower themselves to confidently navigate the future, innovate at a faster pace and lead with assurance in the exciting and complex age of AI. Forbes Technology Council is an invitation-only community for world-class CIOs, CTOs and technology executives. Do I qualify?
Yahoo
an hour ago
- Yahoo
Kosmos Energy (KOS) Soars 7.7% Ahead of Q2 Earnings
We recently published . Kosmos Energy Ltd. (NYSE:KOS) is one of the best-performing stocks on Monday. Kosmos Energy saw its share prices increase by 7.66 percent on Monday to close at $2.39 apiece as investors repositioned portfolios ahead of its earnings release next week. According to the company, it is scheduled to release the results of its financial and operating highlights on August 4, 2025. An investor call will be held on the same day to elaborate on the results. Based on its guidance announced earlier this year, Kosmos Energy Ltd. (NYSE:KOS) said it was targeting to produce between 66,000 and 72,000 barrels of oil per day (boe/d) for the second quarter of the year, and between 70,000 to 80,000 boe/d for full-year 2025. In the first quarter alone, the company was able to produce 60,500 boe/d. Copyright: Elnur / 123RF Stock Photo Also in the first quarter, Kosmos Energy Ltd. (NYSE:KOS) swung to a net loss of $110.6 million from a $91.7 million net income in the same period last year. Total revenues and other income ended at $290 million, lower by 31 percent than the $419 million in the same period last year. While we acknowledge the potential of KOS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the .
